The FDA has granted orphan drug designation to Cure Rare Disease’s CRD-002, an antisense oligonucleotide therapeutic for the treatment of spinocerebellar ataxia (SCA), including spinocerebellar ataxia ...

Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a ...

The Department of Neurology at Niigata University and the National Center of Neurology and Psychiatry (NCNP) have identified pathogenic thresholds for the CAG repeat units (RU) of the CACNA1A gene ...

Stefan Pulst, a neurologist at the University of Utah, sees hundreds of patients each year with puzzling brain diseases. But 15 years ago, he met a patient whom he thought could be the key to solving ...

Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...

Noninvasive neurostimulation delivered to the brain and spinal cord significantly reduces symptoms of rare, neurodegenerative ataxias, a new first-in-humans trial shows. Cerebellar anodal and spinal ...